EUVIMEDEUVIMED entdecken
Crossref

Ciprofloxacin-susceptible but levofloxacin-resistant Pseudomonas aeruginosa clinical strains with Vitek®2: which mechanism involved and consequences in case of fluoroquinolone treatment?

Manon Robert, Louise Ruffier d'Epenoux, Axelle Paquin, David Boutoille, Aurélie Guillouzouic, Stéphane Corvec

European Journal of Clinical Microbiology & Infectious Diseases · 2025

DOI: 10.1007/s10096-024-05006-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2025. Verfasst von Manon Robert und 5 weiteren Autor:innen. Beteiligte Einrichtung: Service de Bactériologie et des Contrôles Microbiologiques, CHU Nantes, Nantes, France. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Levofloxacin, Anti-Bacterial Agents, Ciprofloxacin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaLevofloxacinAnti-Bacterial AgentsCiprofloxacinFluoroquinolonesPseudomonas InfectionsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMutationMaleFemaleDrug Resistance, Multiple, BacterialMiddle AgedBacterial Proteins

Stichwörter der Autor:innen

P. aeruginosaCiprofloxacinIn vivo selectionLevofloxacinMICResistance

Substanzen

LevofloxacinAnti-Bacterial AgentsCiprofloxacinFluoroquinolonesBacterial Proteins

Autor:innen und Institutionen

  • Service de Bactériologie et des Contrôles Microbiologiques, CHU Nantes, Nantes, France.
  • INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes Université, Nantes, France.
  • Service des Maladies Infectieuses, Hôtel-Dieu, Centre Hospitalier Universitaire, Nantes, France.
  • Centre d'Investigation Clinique Unité d'Investigation Clinique, Centre Hospitalier Universitaire, Nantes, France.
  • Service de Bactériologie et des Contrôles Microbiologiques, CHU Nantes, Nantes, France. stephane.corvec@chu-nantes.fr.
  • INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes Université, Nantes, France. stephane.corvec@chu-nantes.fr.

Zitieren

APA

Robert, M., Ruffier d'Epenoux, L., Paquin, A., Boutoille, D., Guillouzouic, A., & Corvec, S. (2025). Ciprofloxacin-susceptible but levofloxacin-resistant Pseudomonas aeruginosa clinical strains with Vitek®2: which mechanism involved and consequences in case of fluoroquinolone treatment?. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-05006-3

Vancouver

Robert M, Ruffier d'Epenoux L, Paquin A, Boutoille D, Guillouzouic A, Corvec S. Ciprofloxacin-susceptible but levofloxacin-resistant Pseudomonas aeruginosa clinical strains with Vitek®2: which mechanism involved and consequences in case of fluoroquinolone treatment?. European Journal of Clinical Microbiology & Infectious Diseases. 2025. doi:10.1007/s10096-024-05006-3

BibTeX
@article{Robert2025,
  author = {Robert, Manon and Ruffier d'Epenoux, Louise and Paquin, Axelle and Boutoille, David and Guillouzouic, Aurélie and Corvec, Stéphane},
  title = {Ciprofloxacin-susceptible but levofloxacin-resistant Pseudomonas aeruginosa clinical strains with Vitek®2: which mechanism involved and consequences in case of fluoroquinolone treatment?},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2025},
  doi = {10.1007/s10096-024-05006-3}
}
Kostenlos starten →